ASH/AABB Joint Program: Support and Therapy for Myelodysplastic Syndromes
Program Code: 9314-TC
Monday, October 26, 2009
10:30 AM to 12:00 PM (ET)

MODERATOR
Mikkael Sekeres, MD, MS, The Cleveland Clinic Taussig Cancer Institute

SPEAKERS
Mikkael Sekeres, MD, MS, The Cleveland Clinic Taussig Cancer Institute
David Steensma, MD, Mayo Clinic

DESCRIPTION
The myelodysplastic syndromes (MDS), considered a form of leaukemia, are diagnosed in over 10,000 people yearly in the United States. These diseases result in significant peripheral blood cytopenias, often necessitating transfusion of blood products. This session will review the pathobiology and epidemiology of these diseases; the impact of transfusion needs and appropriate use of erythropoiesis stimulating agents in this population; and appropriate use of iron chelation therapy in MDS patients.